study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients.
- Registry ID
- EUCTR2013-003016-45
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Araim Pharmaceuticals
- Start date
- 2013-08-14
- Completion date
- 2015-02-02
- Last update
- 2026-08-16
Conditions
Summary
To evaluate the efficacy of different dose levels of ARA 290 administration on different outcome measures of small fiber neuropathy in subjects with sarcoidosis.
Locations
View on source registry